Sports
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
LYON, France, July 24, 2025--MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
About this update from Maat Pharma
LYON, France, July 24, 2025 --( BUSINESS WIRE )--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux. Under the liquidity contract entered between MaaT Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30 th , 2025: As a reminder: The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22 nd , 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. View source version on businesswire.com: https://www.businesswire.com/news/home/20250724345351/en/ Contacts MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected] MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected] Catalytic Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected]